Cargando…
Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC
INTRODUCTION: After palliative radiotherapy for bone metastases from NSCLC, up to 30% of patients may derive no symptomatic benefit, and there are a lack of biological predictors for this. The purpose was to investigate whether EGFR and ALK genetic rearrangements were associated with greater rates o...
Autores principales: | Sit, Daegan, Bale, Michelle, Lapointe, Vincent, Olson, Robert, Hsu, Fred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356089/ https://www.ncbi.nlm.nih.gov/pubmed/35941996 http://dx.doi.org/10.1016/j.jtocrr.2022.100371 |
Ejemplares similares
-
Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study
por: Hsu, Fred, et al.
Publicado: (2021) -
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014) -
Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022) -
ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011) -
ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)